Phenotype-specific therapeutic efficacy of ilofotase alfa in patients with sepsis-associated acute kidney injury
Authors' conclusion
We identified a clinical phenotype comprising severely ill patients with underlying kidney disease who benefitted most from ilofotase alfa treatment.
Study context
- Population
- Patients with sepsis-associated AKI (sepsis-associated acute kidney injury (SA-AKI)) enrolled in the REVIVAL trialof 650 enrolled
- Participants
- 570 patients
- Comparison
- Ilofotase alfa vs placebo, by clinical phenotype
- Primary endpoint
- Major Adverse Kidney Events (MAKE90) by phenotype
- Follow-up
- Up to day 90
Methodological detailsmachine learning, clustering analysis, phenotype analysis
- Machine learning
- Clustering analysis
- Phenotype analysis
Primary result
As reported in the abstract
MAKE90 events by phenotype
- Ilofotase alfa significantly reduced MAKE90 vs placebo in phenotype 2 but not in phenotype 1
- Ilofotase alfa vs Placebo: P = 0.013
- Ilofotase alfa vs Placebo: P = 0.54
- MAKE90 was the trial's main secondary endpoint
- Optimal clustering model: two phenotypes
Original publication
Phenotype-specific therapeutic efficacy of ilofotase alfa in patients with sepsis-associated acute kidney injury. Crit Care. Published 19 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →